Verve Therapeutics (VERV) Peer Comparison

$11.13

$0.00 (0.00%)

As on 25-Jul-2025 09:30EDT

Market cap

$994 Mln

Revenue (TTM)

$60 Mln

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Edit

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Market cap ($ Mln)	994	719
Revenue ($ Mln)	60	--
Net Profit ($ Mln)	-181.01	-30.74
Net Margin (%)	-303.64	--
RoE (%)	-36.86	-25.42
Price to Earnings	--	--
Price-To-Book	2.10	6.20

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Operating Revenue	59.61	0.00
Cost of Revenue	5.12	0.18
Gross Profit	32.33	-0.49
Operating Expenses	268.07	44.47
Operating Profit (EBIT)	-208.45	-44.16
Other Income	0.00	0.00
Profit before Tax	-180.68	-30.64
Provision for Tax	0.32	0.02
Profit after Tax (Net Income)	-181.01	-30.74
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Shareholder's Funds	473.51	115.91
Minority Interest	0.00	0.00
Non-Current Liabilities	88.67	2.94
Current Liabilities	51.98	7.32
Total Liabilities	647.39	141.51

Assets ($ Mln)

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Non-Current Assets	102.51	27.15
Current Assets	511.65	99.01
Total Assets	647.39	141.51
Total Debt*	68.64	5.68
Net Current Assets	459.67	91.69

Cashflow ($ Mln)

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Cash From Operating Activities	-157.69	-46.00
Cash Flow from Investing Activities	74.88	-34.90
Cash from Financing Activities	49.20	0.00
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
ROCE (%)	-32.11	-31.36
ROE (%)	-36.86	-25.42
ROA (%)	-25.32	-20.55
EBIT Margin (%)	-349.68	--
Net Margin (%)	-303.64	--
Cash Profit Margin (%)	0.00	--

Growth Ratios

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Revenue Growth (%)	271.44	-1.00
EBIT Growth (%)	7.41	41.87
Net Profit Growth (%)	8.04	53.91
EPS Growth (%)	26.65	55.32
Book Value Growth (%)	-23.97	-18.87

Valuation Ratios

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Price / Earnings	-2.47	-1.61
Price / Book Value	0.99	0.63
Dividend Yield (%)	--	--
EV/EBITDA	-0.16	0.78
Market Cap ($ Cr)	--	--

Solvency Ratios

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.02	0.03
Current Ratio	9.84	13.52
Quick Ratio	9.84	13.52
Interest Coverage	--	--

Operating Efficiency Ratios

	Verve Therapeutics (VERV)	Ikena Oncology (IKNA)
Debtors to sales (%)	2.35	--
Asset Turnover	0.08	0.00
Receivable days	51.69	--
Inventory Days	0.00	--
Payable days	301.70	1,104.32
Cash Conversion Cycle	-250.00	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly